nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—LTK—tongue—salivary gland cancer	0.0416	0.136	CbGeAlD
Erlotinib—ULK3—tongue—salivary gland cancer	0.0226	0.0737	CbGeAlD
Erlotinib—JAK3—connective tissue—salivary gland cancer	0.0137	0.0446	CbGeAlD
Erlotinib—PIP4K2C—parotid gland—salivary gland cancer	0.0111	0.0361	CbGeAlD
Erlotinib—FLT3—connective tissue—salivary gland cancer	0.0108	0.0352	CbGeAlD
Erlotinib—PIP4K2C—saliva-secreting gland—salivary gland cancer	0.0106	0.0346	CbGeAlD
Erlotinib—ULK3—parotid gland—salivary gland cancer	0.0106	0.0345	CbGeAlD
Erlotinib—ULK3—saliva-secreting gland—salivary gland cancer	0.0101	0.0331	CbGeAlD
Erlotinib—JAK3—lymphoid tissue—salivary gland cancer	0.01	0.0326	CbGeAlD
Erlotinib—SLK—parotid gland—salivary gland cancer	0.00944	0.0308	CbGeAlD
Erlotinib—SLK—saliva-secreting gland—salivary gland cancer	0.00904	0.0295	CbGeAlD
Erlotinib—FLT3—lymphoid tissue—salivary gland cancer	0.0079	0.0257	CbGeAlD
Erlotinib—MAP2K5—parotid gland—salivary gland cancer	0.00733	0.0239	CbGeAlD
Erlotinib—LTK—lymph node—salivary gland cancer	0.00707	0.023	CbGeAlD
Erlotinib—MAP2K5—saliva-secreting gland—salivary gland cancer	0.00702	0.0229	CbGeAlD
Erlotinib—MKNK1—lymphoid tissue—salivary gland cancer	0.00641	0.0209	CbGeAlD
Erlotinib—AURKC—lymph node—salivary gland cancer	0.0061	0.0199	CbGeAlD
Erlotinib—ABL1—parotid gland—salivary gland cancer	0.00565	0.0184	CbGeAlD
Erlotinib—JAK3—lymph node—salivary gland cancer	0.00565	0.0184	CbGeAlD
Erlotinib—ABL1—saliva-secreting gland—salivary gland cancer	0.00542	0.0176	CbGeAlD
Erlotinib—STK10—lymphoid tissue—salivary gland cancer	0.00528	0.0172	CbGeAlD
Erlotinib—TNK1—lymph node—salivary gland cancer	0.00519	0.0169	CbGeAlD
Erlotinib—ABL1—connective tissue—salivary gland cancer	0.00498	0.0162	CbGeAlD
Erlotinib—FLT3—lymph node—salivary gland cancer	0.00446	0.0145	CbGeAlD
Erlotinib—ABL2—lymph node—salivary gland cancer	0.00426	0.0139	CbGeAlD
Erlotinib—CYP1B1—connective tissue—salivary gland cancer	0.00421	0.0137	CbGeAlD
Erlotinib—EGFR—lymph node—salivary gland cancer	0.00415	0.0135	CbGeAlD
Erlotinib—PIP4K2C—lymph node—salivary gland cancer	0.00403	0.0131	CbGeAlD
Erlotinib—ULK3—lymph node—salivary gland cancer	0.00384	0.0125	CbGeAlD
Erlotinib—ABL1—lymphoid tissue—salivary gland cancer	0.00364	0.0119	CbGeAlD
Erlotinib—MKNK1—lymph node—salivary gland cancer	0.00362	0.0118	CbGeAlD
Erlotinib—ABCG2—parotid gland—salivary gland cancer	0.00357	0.0116	CbGeAlD
Erlotinib—SLK—lymph node—salivary gland cancer	0.00343	0.0112	CbGeAlD
Erlotinib—ABCG2—saliva-secreting gland—salivary gland cancer	0.00341	0.0111	CbGeAlD
Erlotinib—CYP1A1—parotid gland—salivary gland cancer	0.00339	0.011	CbGeAlD
Erlotinib—CYP1B1—lymphoid tissue—salivary gland cancer	0.00308	0.01	CbGeAlD
Erlotinib—STK10—lymph node—salivary gland cancer	0.00298	0.00971	CbGeAlD
Erlotinib—CYP1A1—epithelium—salivary gland cancer	0.00283	0.00922	CbGeAlD
Erlotinib—MAP2K5—lymph node—salivary gland cancer	0.00266	0.00867	CbGeAlD
Erlotinib—ORM1—lymph node—salivary gland cancer	0.00216	0.00704	CbGeAlD
Erlotinib—SLCO2B1—lymph node—salivary gland cancer	0.00207	0.00675	CbGeAlD
Erlotinib—ABL1—lymph node—salivary gland cancer	0.00205	0.00669	CbGeAlD
Erlotinib—ALB—lymph node—salivary gland cancer	0.00189	0.00617	CbGeAlD
Erlotinib—CYP1B1—lymph node—salivary gland cancer	0.00174	0.00567	CbGeAlD
Erlotinib—ABCB1—epithelium—salivary gland cancer	0.00147	0.00479	CbGeAlD
Erlotinib—ABCG2—lymph node—salivary gland cancer	0.00129	0.00422	CbGeAlD
Erlotinib—CYP1A1—lymph node—salivary gland cancer	0.00123	0.00401	CbGeAlD
Erlotinib—ABCB1—lymphoid tissue—salivary gland cancer	0.00113	0.00369	CbGeAlD
Erlotinib—ABCB1—lymph node—salivary gland cancer	0.000638	0.00208	CbGeAlD
Erlotinib—EGFR—Signaling by EGFR in Cancer—HRAS—salivary gland cancer	0.000136	0.000196	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—HRAS—salivary gland cancer	0.000135	0.000195	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CREBBP—salivary gland cancer	0.000135	0.000194	CbGpPWpGaD
Erlotinib—MKNK1—Disease—PTEN—salivary gland cancer	0.000134	0.000193	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MAP2K2—salivary gland cancer	0.000133	0.000192	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGFR4—salivary gland cancer	0.000133	0.000192	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FOXO3—salivary gland cancer	0.000133	0.000192	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—PIK3CA—salivary gland cancer	0.000132	0.000191	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CREBBP—salivary gland cancer	0.000131	0.000189	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FBXW7—salivary gland cancer	0.000131	0.000189	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—HRAS—salivary gland cancer	0.00013	0.000188	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—CREBBP—salivary gland cancer	0.00013	0.000188	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FOXO3—salivary gland cancer	0.000129	0.000186	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PHGDH—salivary gland cancer	0.000129	0.000186	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MARCKS—salivary gland cancer	0.000128	0.000185	CbGpPWpGaD
Erlotinib—MKNK1—Disease—EP300—salivary gland cancer	0.000128	0.000184	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—HRAS—salivary gland cancer	0.000128	0.000184	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—salivary gland cancer	0.000128	0.000184	CbGpPWpGaD
Erlotinib—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—salivary gland cancer	0.000126	0.000181	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ISYNA1—salivary gland cancer	0.000126	0.000181	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—NUP62—salivary gland cancer	0.000125	0.00018	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ST3GAL4—salivary gland cancer	0.000124	0.000179	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—VCAN—salivary gland cancer	0.000124	0.000179	CbGpPWpGaD
Erlotinib—EGFR—Disease—JAG1—salivary gland cancer	0.000123	0.000178	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGFR4—salivary gland cancer	0.000123	0.000177	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—salivary gland cancer	0.000122	0.000176	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PHGDH—salivary gland cancer	0.000122	0.000176	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MARCKS—salivary gland cancer	0.000121	0.000175	CbGpPWpGaD
Erlotinib—EGFR—Disease—FBXW7—salivary gland cancer	0.000121	0.000174	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	0.000119	0.000172	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PYGB—salivary gland cancer	0.000119	0.000172	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—salivary gland cancer	0.000118	0.00017	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ST3GAL4—salivary gland cancer	0.000117	0.000169	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF16—salivary gland cancer	0.000117	0.000168	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CREBBP—salivary gland cancer	0.000115	0.000166	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AQP1—salivary gland cancer	0.000113	0.000163	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PYGB—salivary gland cancer	0.000112	0.000162	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PHGDH—salivary gland cancer	0.000112	0.000161	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PHGDH—salivary gland cancer	0.000111	0.00016	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FOXO3—salivary gland cancer	0.00011	0.000159	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CDH1—salivary gland cancer	0.00011	0.000158	CbGpPWpGaD
Erlotinib—JAK3—Immune System—PTEN—salivary gland cancer	0.000109	0.000158	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NOTCH1—salivary gland cancer	0.000109	0.000158	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAP2K2—salivary gland cancer	0.000109	0.000157	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ST3GAL4—salivary gland cancer	0.000107	0.000155	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ST3GAL4—salivary gland cancer	0.000107	0.000154	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AQP1—salivary gland cancer	0.000106	0.000154	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAP2K2—salivary gland cancer	0.000106	0.000152	CbGpPWpGaD
Erlotinib—JAK3—Immune System—EP300—salivary gland cancer	0.000104	0.00015	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—salivary gland cancer	0.000104	0.00015	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—EP300—salivary gland cancer	0.000104	0.00015	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	0.000103	0.000149	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MARCKS—salivary gland cancer	0.000102	0.000148	CbGpPWpGaD
Erlotinib—EGFR—Disease—FOXO3—salivary gland cancer	0.000102	0.000147	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—EP300—salivary gland cancer	0.000102	0.000147	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—PIK3CA—salivary gland cancer	0.000102	0.000147	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAML2—salivary gland cancer	0.000101	0.000146	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—salivary gland cancer	0.0001	0.000145	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—HRAS—salivary gland cancer	9.96e-05	0.000144	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CREBBP—salivary gland cancer	9.9e-05	0.000143	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAP2K2—salivary gland cancer	9.87e-05	0.000142	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AQP1—salivary gland cancer	9.76e-05	0.000141	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PHGDH—salivary gland cancer	9.73e-05	0.00014	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CCND1—salivary gland cancer	9.72e-05	0.00014	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AQP1—salivary gland cancer	9.71e-05	0.00014	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ISYNA1—salivary gland cancer	9.7e-05	0.00014	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—PTEN—salivary gland cancer	9.61e-05	0.000139	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—salivary gland cancer	9.58e-05	0.000138	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PYGB—salivary gland cancer	9.53e-05	0.000137	CbGpPWpGaD
Erlotinib—MKNK1—Disease—PIK3CA—salivary gland cancer	9.45e-05	0.000136	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—HRAS—salivary gland cancer	9.4e-05	0.000136	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—PTEN—salivary gland cancer	9.38e-05	0.000135	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ST3GAL4—salivary gland cancer	9.37e-05	0.000135	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—PIK3CA—salivary gland cancer	9.3e-05	0.000134	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—EP300—salivary gland cancer	9.17e-05	0.000132	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PHGDH—salivary gland cancer	9.17e-05	0.000132	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAP2K2—salivary gland cancer	9.02e-05	0.00013	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EP300—salivary gland cancer	8.94e-05	0.000129	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NUP62—salivary gland cancer	8.94e-05	0.000129	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NOTCH1—salivary gland cancer	8.9e-05	0.000128	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—EP300—salivary gland cancer	8.87e-05	0.000128	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—VCAN—salivary gland cancer	8.87e-05	0.000128	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ST3GAL4—salivary gland cancer	8.83e-05	0.000127	CbGpPWpGaD
Erlotinib—MKNK1—Disease—HRAS—salivary gland cancer	8.74e-05	0.000126	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JAG1—salivary gland cancer	8.64e-05	0.000125	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGFR4—salivary gland cancer	8.61e-05	0.000124	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	8.53e-05	0.000123	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—HRAS—salivary gland cancer	8.51e-05	0.000123	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AQP1—salivary gland cancer	8.5e-05	0.000123	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FBXW7—salivary gland cancer	8.47e-05	0.000122	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—PIK3CA—salivary gland cancer	8.45e-05	0.000122	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NUP62—salivary gland cancer	8.44e-05	0.000122	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—VCAN—salivary gland cancer	8.38e-05	0.000121	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAP2K2—salivary gland cancer	8.33e-05	0.00012	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—PTEN—salivary gland cancer	8.22e-05	0.000119	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	8.13e-05	0.000117	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CREBBP—salivary gland cancer	8.07e-05	0.000116	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AQP1—salivary gland cancer	8.01e-05	0.000116	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MARCKS—salivary gland cancer	7.91e-05	0.000114	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PTEN—salivary gland cancer	7.89e-05	0.000114	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CREBBP—salivary gland cancer	7.84e-05	0.000113	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—EP300—salivary gland cancer	7.83e-05	0.000113	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—HRAS—salivary gland cancer	7.81e-05	0.000113	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CDH1—salivary gland cancer	7.78e-05	0.000112	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PHGDH—salivary gland cancer	7.77e-05	0.000112	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NUP62—salivary gland cancer	7.74e-05	0.000112	CbGpPWpGaD
Erlotinib—JAK3—Immune System—PIK3CA—salivary gland cancer	7.72e-05	0.000111	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NUP62—salivary gland cancer	7.7e-05	0.000111	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—VCAN—salivary gland cancer	7.68e-05	0.000111	CbGpPWpGaD
Erlotinib—ALB—Metabolism—VCAN—salivary gland cancer	7.64e-05	0.00011	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—PIK3CA—salivary gland cancer	7.53e-05	0.000109	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ST3GAL4—salivary gland cancer	7.48e-05	0.000108	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—CREBBP—salivary gland cancer	7.36e-05	0.000106	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PYGB—salivary gland cancer	7.35e-05	0.000106	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	7.35e-05	0.000106	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCND1—salivary gland cancer	7.33e-05	0.000106	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—salivary gland cancer	7.29e-05	0.000105	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—PIK3CA—salivary gland cancer	7.19e-05	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FOXO3—salivary gland cancer	7.14e-05	0.000103	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HRAS—salivary gland cancer	7.14e-05	0.000103	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—HRAS—salivary gland cancer	7.11e-05	0.000103	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—salivary gland cancer	7.08e-05	0.000102	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PTEN—salivary gland cancer	7.07e-05	0.000102	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—HRAS—salivary gland cancer	6.97e-05	0.000101	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—salivary gland cancer	6.85e-05	9.89e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—NOTCH1—salivary gland cancer	6.82e-05	9.84e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AQP1—salivary gland cancer	6.79e-05	9.79e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—PIK3CA—salivary gland cancer	6.78e-05	9.78e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EP300—salivary gland cancer	6.74e-05	9.73e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NUP62—salivary gland cancer	6.74e-05	9.73e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	6.74e-05	9.72e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	6.7e-05	9.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CREBBP—salivary gland cancer	6.7e-05	9.67e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—VCAN—salivary gland cancer	6.69e-05	9.65e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDH1—salivary gland cancer	6.65e-05	9.59e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—PIK3CA—salivary gland cancer	6.62e-05	9.54e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—salivary gland cancer	6.4e-05	9.23e-05	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	6.37e-05	9.19e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NUP62—salivary gland cancer	6.35e-05	9.17e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—VCAN—salivary gland cancer	6.3e-05	9.1e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—HRAS—salivary gland cancer	6.28e-05	9.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CREBBP—salivary gland cancer	6.19e-05	8.92e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HRAS—salivary gland cancer	6.12e-05	8.83e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HRAS—salivary gland cancer	6.07e-05	8.76e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	6.01e-05	8.68e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PHGDH—salivary gland cancer	5.99e-05	8.65e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCND1—salivary gland cancer	5.97e-05	8.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAP2K2—salivary gland cancer	5.83e-05	8.41e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—PIK3CA—salivary gland cancer	5.8e-05	8.36e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ST3GAL4—salivary gland cancer	5.77e-05	8.32e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PTEN—salivary gland cancer	5.77e-05	8.32e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CREBBP—salivary gland cancer	5.7e-05	8.22e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PTEN—salivary gland cancer	5.6e-05	8.08e-05	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	5.58e-05	8.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PIK3CA—salivary gland cancer	5.57e-05	8.03e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EP300—salivary gland cancer	5.5e-05	7.93e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NUP62—salivary gland cancer	5.38e-05	7.77e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—salivary gland cancer	5.36e-05	7.74e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—VCAN—salivary gland cancer	5.34e-05	7.71e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EP300—salivary gland cancer	5.34e-05	7.7e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CREBBP—salivary gland cancer	5.32e-05	7.67e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	5.25e-05	7.57e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AQP1—salivary gland cancer	5.24e-05	7.56e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—salivary gland cancer	5.15e-05	7.43e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—EP300—salivary gland cancer	5.01e-05	7.23e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	5.01e-05	7.22e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PIK3CA—salivary gland cancer	4.99e-05	7.2e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CREBBP—salivary gland cancer	4.84e-05	6.98e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—salivary gland cancer	4.83e-05	6.96e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	4.81e-05	6.94e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	4.79e-05	6.9e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PTEN—salivary gland cancer	4.79e-05	6.9e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOTCH1—salivary gland cancer	4.78e-05	6.89e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	4.69e-05	6.76e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—salivary gland cancer	4.62e-05	6.66e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	4.59e-05	6.62e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	4.56e-05	6.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—EP300—salivary gland cancer	4.56e-05	6.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTEN—salivary gland cancer	4.42e-05	6.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CREBBP—salivary gland cancer	4.33e-05	6.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—EP300—salivary gland cancer	4.21e-05	6.08e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NUP62—salivary gland cancer	4.15e-05	5.99e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—VCAN—salivary gland cancer	4.12e-05	5.95e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—salivary gland cancer	4.07e-05	5.87e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—salivary gland cancer	4.07e-05	5.87e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—salivary gland cancer	3.95e-05	5.7e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—salivary gland cancer	3.93e-05	5.68e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—EP300—salivary gland cancer	3.88e-05	5.6e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—salivary gland cancer	3.8e-05	5.48e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—salivary gland cancer	3.76e-05	5.43e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—salivary gland cancer	3.71e-05	5.35e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	3.7e-05	5.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—salivary gland cancer	3.69e-05	5.33e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—salivary gland cancer	3.65e-05	5.27e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—EP300—salivary gland cancer	3.62e-05	5.22e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—salivary gland cancer	3.59e-05	5.18e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CREBBP—salivary gland cancer	3.47e-05	5e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—salivary gland cancer	3.45e-05	4.98e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—salivary gland cancer	3.43e-05	4.95e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—salivary gland cancer	3.42e-05	4.93e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	3.4e-05	4.9e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	3.38e-05	4.87e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—salivary gland cancer	3.38e-05	4.87e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	3.35e-05	4.83e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—EP300—salivary gland cancer	3.29e-05	4.75e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CREBBP—salivary gland cancer	3.27e-05	4.72e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—salivary gland cancer	3.21e-05	4.62e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	3.19e-05	4.61e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—salivary gland cancer	3.12e-05	4.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—salivary gland cancer	3.12e-05	4.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—salivary gland cancer	3.09e-05	4.46e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CREBBP—salivary gland cancer	3e-05	4.33e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CREBBP—salivary gland cancer	2.98e-05	4.31e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EP300—salivary gland cancer	2.95e-05	4.26e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—salivary gland cancer	2.88e-05	4.16e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—salivary gland cancer	2.87e-05	4.14e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—salivary gland cancer	2.68e-05	3.86e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CREBBP—salivary gland cancer	2.61e-05	3.77e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—salivary gland cancer	2.47e-05	3.57e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CREBBP—salivary gland cancer	2.46e-05	3.55e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—salivary gland cancer	2.44e-05	3.52e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	2.36e-05	3.41e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—EP300—salivary gland cancer	2.36e-05	3.4e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—salivary gland cancer	2.34e-05	3.37e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—EP300—salivary gland cancer	2.23e-05	3.22e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—salivary gland cancer	2.18e-05	3.15e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—salivary gland cancer	2.14e-05	3.09e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—salivary gland cancer	2.13e-05	3.07e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—salivary gland cancer	2.11e-05	3.05e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CREBBP—salivary gland cancer	2.09e-05	3.01e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—EP300—salivary gland cancer	2.04e-05	2.95e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—EP300—salivary gland cancer	2.03e-05	2.93e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—salivary gland cancer	2.02e-05	2.91e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—salivary gland cancer	1.87e-05	2.69e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—EP300—salivary gland cancer	1.78e-05	2.57e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—salivary gland cancer	1.76e-05	2.54e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—salivary gland cancer	1.75e-05	2.52e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—EP300—salivary gland cancer	1.68e-05	2.42e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—salivary gland cancer	1.65e-05	2.38e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CREBBP—salivary gland cancer	1.61e-05	2.32e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—salivary gland cancer	1.51e-05	2.18e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—salivary gland cancer	1.5e-05	2.17e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—salivary gland cancer	1.49e-05	2.15e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—EP300—salivary gland cancer	1.42e-05	2.05e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—salivary gland cancer	1.32e-05	1.9e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—salivary gland cancer	1.24e-05	1.79e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—salivary gland cancer	1.15e-05	1.66e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—EP300—salivary gland cancer	1.1e-05	1.58e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—salivary gland cancer	1.05e-05	1.52e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—salivary gland cancer	8.12e-06	1.17e-05	CbGpPWpGaD
